Beam Therapeutics Inc.

NASDAQ:BEAM

19.94 (USD) • At close September 8, 2025
Bedrijfsnaam Beam Therapeutics Inc.
Symbool BEAM
Munteenheid USD
Prijs 19.94
Beurswaarde 2,017,170,280
Dividendpercentage 0%
52-weken bereik 13.525 - 35.25
Industrie Biotechnology
Sector Healthcare
CEO Mr. John M. Evans M.B.A.
Website https://www.beamtx.com

An error occurred while fetching data.

Over Beam Therapeutics Inc.

Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor

Vergelijkbare Aandelen

PTC Therapeutics, Inc. logo

PTC Therapeutics, Inc.

PTCT

56.95 USD

Tilray Brands, Inc. logo

Tilray Brands, Inc.

TLRY

1.12 USD

Arvinas, Inc. logo

Arvinas, Inc.

ARVN

7.94 USD

EQRx, Inc. logo

EQRx, Inc.

EQRX

2.34 USD

Iovance Biotherapeutics, Inc. logo

Iovance Biotherapeutics, Inc.

IOVA

2.38 USD

Corcept Therapeutics Incorporated logo

Corcept Therapeutics Incorporated

CORT

71.23 USD

Insmed Incorporated logo

Insmed Incorporated

INSM

146.68 USD

AbCellera Biologics Inc. logo

AbCellera Biologics Inc.

ABCL

4.17 USD

Fate Therapeutics, Inc. logo

Fate Therapeutics, Inc.

FATE

0.966 USD

Canopy Growth Corporation logo

Canopy Growth Corporation

CGC

1.35 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)